We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.4B
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+30.69%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.46B
AUM Growth
+$453M
(+9%)
Cap. Flow
-$312M
Cap. Flow
% of AUM
-5.72%
Top 10 Holdings %
Top 10 Hldgs %
38.94%
Holding
132
New
22
Increased
22
Reduced
29
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ArriVent BioPharma
AVBP
|
+$61.1M |
| 2 |
Cytokinetics
CYTK
|
+$52.8M |
| 3 |
ESPR
Esperion Therapeutics
ESPR
|
+$33.3M |
| 4 |
Merck
MRK
|
+$32.2M |
| 5 |
Q32 Bio
QTTB
|
+$31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
+$147M |
| 2 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
+$93.5M |
| 3 |
United Therapeutics
UTHR
|
+$84.9M |
| 4 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
+$71.7M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$69.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.1% |
| 2 | Miscellaneous | 0.9% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vaxcyte
PCVX
$8.9B
| $72.8M | 1.33% |
1,066,131
-86,960
| -8% | -$6.02M |
|
27
Crinetics Pharmaceuticals
CRNX
$9B
| $64.8M | 1.19% |
1,385,000
-282,360
| -17% | -$11M |
|
28
Scholar Rock
SRRK
$7.04B
| $63.5M | 1.16% |
3,574,632
-670,368
| -16% | -$10.6M |
|
29
argenx
ARGX
$64B
| $59.7M | 1.09% |
151,600
+67,000
| +79% | +$26M |
|
30
Icon
ICLR
$13.1B
| $58.5M | 1.07% |
174,100
+41,900
| +32% | +$12.4M |
|
31
Neurocrine Biosciences
NBIX
$15.7B
| $58.4M | 1.07% |
423,100
-96,179
| -19% | -$13.1M |
|
|
VRNA
32
DELISTED
Verona Pharma
VRNA
| $54.7M | 1% |
3,398,067
-379,711
| -10% | -$6.57M |
|
|
THRD
33
DELISTED
Third Harmonic Bio
THRD
| $54.6M | 1% |
5,779,071
| – | – |
|
|
34
ArriVent BioPharma
AVBP
$1.49B
| $54.1M | 0.99% |
+3,027,328
| New | +$61.1M |
|
35
Neuropace
NPCE
$495M
| $52.9M | 0.97% |
4,003,967
| – | – |
|
36
SI-BONE Inc
SIBN
$861M
| $52M | 0.95% |
3,174,521
+881,990
| +38% | +$16.6M |
|
37
Prelude Therapeutics
PRLD
$437M
| $51.7M | 0.95% |
10,909,256
| – | – |
|
38
Vertex Pharmaceuticals
VRTX
$137B
| $51.3M | 0.94% |
122,700
-52,500
| -30% | -$22.2M |
|
|
TERN
39
DELISTED
Terns Pharmaceuticals
TERN
| $50M | 0.92% |
7,619,135
| – | – |
|
|
40
Cytokinetics
CYTK
$10B
| $47.9M | 0.88% |
+682,700
| New | +$52.8M |
|
41
Apogee Therapeutics
APGE
$10.2B
| $47.8M | 0.87% |
718,901
-559,000
| -44% | -$24.4M |
|
42
Compass Therapeutics
CMPX
$432M
| $44.3M | 0.81% |
22,362,850
| – | – |
|
43
Geron
GERN
$970M
| $42.5M | 0.78% |
12,893,611
+12,408,611
| +2,558% | +$27.8M |
|
44
Syndax Pharmaceuticals
SNDX
$1.74B
| $41.6M | 0.76% |
1,749,000
| – | – |
|
|
45
Q32 Bio
QTTB
$447M
| $38.4M | 0.7% |
+2,252,987
| New | +$31M |
|
|
ESPR
46
DELISTED
Esperion Therapeutics
ESPR
| $36.7M | 0.67% |
+13,708,731
| New | +$33.3M |
|
47
UnitedHealth
UNH
$353B
| $34.6M | 0.63% |
70,000
| – | – |
|
48
Rhythm Pharmaceuticals
RYTM
$7.38B
| $30.5M | 0.56% |
704,842
+168,200
| +31% | +$7.36M |
|
49
ALX Oncology
ALXO
$277M
| $30.3M | 0.56% |
2,717,970
-377,030
| -12% | -$5.3M |
|
50
Vera Therapeutics
VERA
$2.46B
| $29.1M | 0.53% |
675,872
-842,243
| -55% | -$30M |
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q1 2024 Portfolio in Review
As of Q1 2024, OrbiMed held 132 positions worth $5.46B, up 9% from $5.01B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
OrbiMed withdrew a net $312M in Q1 2024, closing 18 positions and reducing 29 holdings. Its most notable exit was RayzeBio, Inc. Common Stock, an estimated $147M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Industrials.
Against the trend, OrbiMed opened a new position in ArriVent BioPharma worth $54.1M.
- OrbiMed's largest Q1 2024 buy was ArriVent BioPharma: 3,027,328 shares worth $54.1M.
- OrbiMed added most to Merck in Q1 2024, an estimated $32.2M increase.
- OrbiMed's biggest Q1 2024 reduction was SpringWorks Therapeutics, cutting an estimated $69.9M.
- OrbiMed fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $147M.
- OrbiMed's ten largest holdings make up 39% of its $5.46B portfolio in Q1 2024.
- OrbiMed opened 22 new positions and closed 18 in Q1 2024.
- OrbiMed's portfolio value rose 9% quarter-over-quarter to $5.46B.
Based on OrbiMed's 13F filing for Q1 2024, filed 15 May 2024.